|Bid||2.0600 x 27000|
|Ask||2.0800 x 2900|
|Day's Range||1.9800 - 2.0950|
|52 Week Range||1.4000 - 6.9100|
|Beta (5Y Monthly)||2.17|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. There was no big news from the biotech company, but clinical-stage biotechs are considered riskier stocks than most, and with the markets dropping in general on Thursday, Affimed's shares took a hit. Investors are waiting to hear next month how two clinical trials are faring for one of the company's lead therapies in AFM13.
Affimed ( NASDAQ:AFMD ) Third Quarter 2022 Results Key Financial Results Revenue: €15.0m (up 69% from 3Q 2021). Net...
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?